Psoriatic Arthritis Therapeutics Market | USD 29.73 Billion by 2034
The global psoriatic arthritis therapeutics market was valued at USD 13.64 billion in 2024 and is projected to reach USD 29.73 billion by 2034, registering a CAGR of 8.1% from 2025 to 2034. The global psoriatic arthritis therapeutics market growth is attributed to the increasing prevalence of psoriatic arthritis across the global.
| Report Coverage | Details |
| Market Size in 2025 | USD 14.75 Billion |
| Market Size by 2034 | USD 29.73 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 8.1% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | By Drug Class, By Product Type, By Route of Administration |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | AbbVie Inc., Janssen Global Services, LLC (Johnson & Johnson), Novartis AG, Amgen Inc., Biogen Inc., Pfizer Inc., Eli Lilly and Company, UCB S.A., Bristol-Myers Squibb Company, Merck & Co. Inc. |
The psoriatic arthritis therapeutics market deals with treatment for individuals with psoriasis who could grow psoriatic arthritis (PsA), a kind of inflammatory arthritis. The aims of therapy are to enhance life, shield joints from harm, and manage symptoms. The market is fragmented with multiple large-scale and small-scale players. The rising advancements in personalized medicine and biologic drugs and increasing awareness about early treatment and diagnosis are expected to drive the growth of the psoriatic arthritis therapeutics market during the forecast period.
There is a major paradigm preference in the treatment of psoriatic arthritis, propelled by the emergence of biosimilars, growing public and private organizations, and the targeted action of biologics. However, the increasing consumer demand for cost-effective medicines with improved efficacy and safety profiles is further expected to drive the growth of the psoriatic arthritis therapeutics market.
Development of Biosimilars Develop Opportunities
Due to the development of biosimilar drugs, the global market can offer growth opportunities. Biosimilars are cheaper generic versions of original biologics. Various pharma companies are in the race to develop high quality biosimilars for these drugs, with patents of some major blockbuster biologics such as Enbrel, Remicade, and Humira expiring in the next few years. Increased biosimilars for these drugs, with patents of some major blockbuster biologics such as Enbrel, Remicade, and Humira expiring in the next few years. Increased adoption of such lower-cost biosimilars can enhance the accessibility and affordability of biologic treatment regimens for psoriatic arthritis patients across the globe, which is further expected to enhance the growth of the psoriatic arthritis therapeutics market in the coming years.
Side effects and adverse reactions hamper market demand.
Healthcare professionals and patients may become concerned about patient safety due to the side effects of psoriatic arthritics therapy. Due to severe adverse effects, the patients may stop taking their recommended medications. Medication non-adherence can lead to limited illness management, which may create major challenges in the therapy. This may reduce people's desire to start specific therapies, which may impact consumer demand negatively and further restrain the growth of the psoriatic arthritis therapeutics market.
The biologics segment dominated the psoriatic arthritis therapeutics market in 2024. The segment growth in the market is propelled by the increasing launches of promising pipeline candidates and strong commercial performances of existing products. Due to ongoing research and development that has produced novel agents, biologics drugs have been increasingly popular and provide physicians and patients additional alternatives. Whereas the non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to grow fastest during the forecast period due to the increasing number of instances of psoriatic arthritis.
The prescriptions segment dominated the psoriatic arthritis therapeutics market in 2024. The psoriatic arthritis can be significantly treated with prescription pharmaceuticals such as targeted synthetic DMARDs, disease-modifying anti-rheumatic drugs, and biologics. In addition, the OTC segment is expected to grow fastest during the forecast period. The segment growth is driven by the availability of over-the-counter medications that can help symptom management.
The injectable segment dominated the psoriatic arthritis therapeutics market in 2024. Most biologics are injected through the intravenous and subcutaneous routes. The segment growth in the market is attributed to the increasing anticipated launches of biosimilars and biologics. The oral segment is expected to grow fastest during the forecast period.
North America dominated the psoriatic arthritis therapeutics market in 2024. The market growth in the region is attributed to the increasing patient access and care to healthcare facilities, well-developed healthcare systems, and an increasing large patient pool. The U.S. and Canada are the dominating countries driving the market growth due to factors such as rising favorable reimbursement policies, proactive government initiatives, and the increasing presence of key manufacturers.
Asia Pacific Market advancements
Asia Pacific is expected to grow fastest during the forecast period. The psoriatic arthritis therapeutics market growth in the region is driven by factors such as a rise in consumer awareness, an increase in disposable income, an improvement in healthcare infrastructure, and overall economic development. China, India, Japan, and South Korea are the fastest growing countries. Due to the result of earlier treatment and diagnosis, the need for efficient therapies has increased, which further drives the market growth in China and India.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Psoriatic Arthritis Therapeutics Market
By Drug Class
By Product Type
By Route of Administration
By Geography
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers